Pioglitazone and risk of mortality in patients with type 2 diabetes: Results from a European multidatabase cohort study

BMJ Open Diabetes Research and Care

Volumn 5, Issue 1, 2017, Pages

  Strongman, Helen ^a   Korhonen, Pasi ^b   Williams, Rachael ^a   Bahmanyar, Shahram ^c   Hoti, Fabian ^b   Christopher, Solomon ^b   Majak, Maila ^b   Kool Houweling, Leanne ^d   Linder, Marie ^c   Dolin, Paul ^e   Heintjes, Edith M ^d  

^a Clinical Practice Research Datalink   (United Kingdom)

^b EPID Research Oy   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^e Takeda Global Research and Development Centre Europe   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC COMA; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KETOACIDOSIS; LIMB DISEASE; LOWER LIMB; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPENSITY SCORE; RETINA MACULOPATHY; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 85019980644     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2016-000364     Document Type: Article

References (26)

1. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123–31.
2. Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001; 322: 1389–93.
3. Rajagopalan S, Dutta P, Hota D, et al. Effect of low dose pioglitazone on glycemic control and insulin resistance in type 2 diabetes: a randomized, double blind, clinical trial. Diabetes Res Clin Pract 2015; 109: e32–e35.
4. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517–23.
5. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. results from the Efficacy and durability of initial combination therapy for type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015; 17: 268–75.
6. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. the pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395–409.
7. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167–74.
8. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093–104.
9. Ceriello A, Johns D, Widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266–72.
10. Mannucci E, Dicembrini I, Lauria A, et al. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care 2013; 36 (Suppl 2): S259–S263.
11. Li W, Katzmarzyk PT, Horswell R, et al. HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol 2016; 202: 490–6.
12. Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud 2014; 11: 138–52.
13. Ekström N, Svensson AM, Miftaraj M, et al. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab 2016; 18: 990–8.
14. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180–8.
15. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 1221–38.
16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet 2005; 366: 1279–89.
17. Yang J, Vallarino C, Bron M, et al. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. Curr Med Res Opin 2014; 30: 2223–31.
18. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 2016; 354: i3477.
19. Medicines and Healthcare products Regulatory Agency. Rosiglitazone: recommended withdrawal from clinical use. 2010 https://www. gov. uk/ drug-safety-update/ rosiglitazonerecommended-withdrawal-from-clinical-use.
20. Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ 2016; 354: i3903.
21. Petri H, Urquhart J. Channeling Bias in the interpretation of drug effects. Stat Med 1991; 10: 577–81.
22. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14–S21.
23. Brown AF, Ettner SL, Piette J, et al. Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev 2004; 26: 63–77.
24. Erdmann E, Harding S, Lam H, et al. Ten-year observational followup of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 2016; 18: 266–73.
25. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 1321–31.
26. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925–31.